KLK4 and prostate carcinoma: The panel of four kallikrein markers also has good predictive accuracy for biopsy outcome and aggressive disease, and tissue biomarkers (i.e., Oncotype DX Prostate Cancer Assay, CCP score) show promising ability for predicting disease progression.